Mar 24,2023

ViCentra now offers Kaleido insulin pump in the Netherlands

ViCentra recently announced that it made its Kaleido insulin pump system available for users in the Netherlands. Kaleido features pulse technology that provides continuous micro-dosing of insulin. Each user can choose to wear the discreet pump directly on the body or in its pocket when using its longer tubing option. Later this year, ViCentra plans to make Kaleido available in combination with the DBLG1 system from Diabeloop connected to Dexcom 6 CGM.

PRODUCT

#insulin pump

#cgm

#closed loop

View Analyst & Ambassador Comments
Go to original news
Mar 21,2023

Manitoba Becomes a Provincial Trailblazer in Providing Simplified Access to Advanced Glucose Monitors

Dexcom, Inc. announced that its Dexcom G6 CGM System will be available to people of all ages with type 1 and type 2 diabetes in Manitoba who meet eligibility criteria. As of this announcement, Manitoba is currently the only province in Canada that does not require an application for preapproval of coverage which means improved access for patients and reduced workload for prescribers.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 20,2023

Electronic Skin Patches: Transforming Everyday Life, Says IDTechEx

In the report, IDTechEx investigates the technologies and applications of electronic skin patches and forecasts that the total market will grow from US$14 billion in 2023 to US$27 billion by 2033. This article delves into the exciting potential of electronic skin patches in shaping everyday life. Beyond heart rate monitoring chest straps and smartwatches, endurance athletes are exploring the use of CGMs. By continuously monitoring glucose levels, athletes can better manage their energy and optimize their performance and training to gain a competitive edge.

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 15,2023

Tandem Diabetes Care Announces NEJM Publication of Study Demonstrating Increased Time in Range in Young Children with Type 1 Diabetes Using the t:slim X2 Insulin Pump with Control-IQ Technology

Tandem Diabetes Care today announced publication of results from the Pediatric Artificial Pancreas (PEDAP) Clinical Trial by the New England Journal of Medicine showing an approximate 3-hour per day increase in time in range in children ages 2-5 years old using the t:slim X2 insulin pump with Control-IQ advanced hybrid closed-loop technology compared to those on a standard insulin pump or multiple daily injections. All participants were using a Dexcom G6 Continuous Glucose Monitoring (CGM) System. Mean time in range with Control-IQ technology increased from 57 percent at baseline to 69 percent during follow-up compared to 55 percent to 56 percent in the control group, for a mean adjusted difference of 12.4 percent. Nighttime mean time in range was 74 percent with Control-IQ technology versus 56 percent in the control group and daytime was 67 percent versus 56 percent, respectively.

CLINICAL STUDY

#cgm

#closed loop

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Mar 15,2023

Nemaura Medical to offer CGM-guided insulin dose titration care model

Nemaura Medical announced today that it now includes insulin under its DuoPack commercial license agreement. Loughborough, UK-based Nemaura Medical entered into a commercial agreement in September 2021 with MySugarWatch DuoPack Limited (MSWDL). Under the agreement, Nemaura’s non-invasive, wearable skin patch sensors paired with prescription-only medicines for type 2 diabetes. This created the MySugarWatch-branded “DuoPack.” The combination of sensors and medicine aimed to provide a “one-stop shop” supported by a holistic care approach. This offering used MSWDL nurses and nutritionists to create a long-term motivational relationship between patient and professional.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 08,2023

Continuous Glucose Monitoring (CGM) Market Report 2023: Sector to Reach $16.69 Billion by 2028 at a 19.16% CAGR

The continuous glucose monitoring market is expected to grow at a CAGR of 19.16%, from an initial value of US$4.896 billion in 2021 to US$16.698 billion by 2028 according to the publisher of the report. The rising investments by companies operating in this segment to commercialize their products are also expected to push the demand for such devices.

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 07,2023

Huge win for continuous glucose monitor (CGM) and insulin pump coverage for people with type 1 diabetes in Manitoba

On March 7, 2023, the government of Manitoba announced that it was investing $120 million in the Manitoba Pharmacare program in part to expand coverage of diabetes devices like insulin pumps and glucose monitors. The province said it will be expanding the program to include all adults who have been diagnosed with type 1 and type 2 diabetes and have a prescription. Prior to this investment, coverage for pumps in Manitoba stopped at age 18 and coverage for advanced glucose monitors stopped at age 25. This announcement comes after significant advocacy from the Manitoba T1D community, with support from JDRF Canada. With coverage of both insulin pumps and CGMs expanding, those living with T1D and can take advantage of integrations for a hybrid-closed loop (HCL) system, which acts as an artificial pancreas.

#cgm

#insulin pump

#closed loop

View Analyst & Ambassador Comments
Go to original news
Mar 07,2023

Sweden Diabetes Market Report 2023: Featuring B. Braun Melsungen, Eli Lilly, Novo Nardisk, Becton, Dickinson, Medtronic & More

Sweden's Diabetes Market will reach US$ 1.86 Billion in 2028 and expand at a CAGR of 4.26% from 2023 to 2028, according to the publisher.

#bgm

#cgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Feb 09,2022

Abbott Diabetes Care and Sugar.fit Partner for Diabetes Care in India

Abbott, the global healthcare leader, announced new collaborations with key health-tech partners Sugar.fit, and 7 other companies in India to usher a new era of holistic diabetes management care. Madan Somasundaram, Co-founder and CEO, Sugar.fit said, "At Sugar.fit, our mission is to empower people with chronic conditions to live better and healthier lives and reverse chronic metabolic disorders. Technology is combined with science and human coaching to help millions of Indians manage and reverse diabetes through a highly consumer-centric data-driven digital health experience."

COLLABORATION PARTNERSHIP

#connected device

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 09,2022

Abbott Diabetes Care India Announces Partnerships with HealthifyMe, GOQii and 7 Others

Abbott, the global healthcare leader, announced new collaborations with key health-tech partners Healthifyme, GOQii and 7 others (BeatO, Sugar.fit, PharmEasy, , 1MG, Zyla Health, and Fitterfly) to usher a new era of holistic diabetes management care. 

COLLABORATION PARTNERSHIP

#connected device

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to CGM